Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)
Starting soon
Conditions studied: Hepatitis B, Chronic
In brief
Chronic hepatitis B is a long-term viral infection that affects millions of people worldwide. Patients usually require lifelong antiviral treatment to control the virus and prevent liver damage. Some older antiviral medications, such as lamivudine, can lead to the development of viral resistance. This means the virus changes in a way that makes certain treatments less effective. Even though newer drugs like entecavir are stronger and more resistant to these changes, previous exposure to lamivudine may increase the risk of developing additional resistance mutations. By analyzing viral genetic material from blood samples using advanced sequencing technology, this research will help improve understanding of antiviral resistance patterns in patients with chronic hepatitis B in Turkey and may support better treatment decisions in the future.
Key facts
- Study ID
- NCT07459426
- Run by
- Yaşar Bayındır, MD
- People needed
- 700
- Starts
- 2026-03-15
- Expected to finish
- 2027-03-15
- Last updated by the study team
- 2026-03-09
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥18 years
- HBsAg positive
- Group 1: Either treatment-naïve participants with HBV DNA>2000 IU/ml
- Group 2: Prior lamivudine therapy ≥6 months with switch to ADVor TDF or TAF
- Ability to provide informed consent
You may not qualify if…
- Prior entecavir exposure
- Prior telbivudine exposure
- Age <18 years
- Inability to provide informed consent Note: Previous adefovir or (pegylated) interferon use is not an exclusion criterion.
- Patients with insufficient sample volume or inadequate DNA quality for sequencing will be excluded from final analysis.
Where it is running
- Gaziantep University — Gaziantep, Turkey (Türkiye)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.